<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685945</url>
  </required_header>
  <id_info>
    <org_study_id>RAAS &amp; Fibrinolysis</org_study_id>
    <secondary_id>2R01HL060906</secondary_id>
    <secondary_id>HL065193</secondary_id>
    <secondary_id>UL1RR024975</secondary_id>
    <secondary_id>5R01HL085740-05</secondary_id>
    <nct_id>NCT00685945</nct_id>
  </id_info>
  <brief_title>Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3</brief_title>
  <official_title>Renin-Angiotensin Aldosterone System and Fibrinolysis(RAAS) Interaction in Humans- Specific Aim 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if giving isosorbide,a drug that is used to treat
      chest pain, affects blood vessel release of an anti-clotting factor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test the hypothesis that the administration of the NO donor isosorbide dinitrate,but not
      the phosphodiesterase inhibitor sildenafil, will attenuate stimulated vascular t-PA release
      whereas both agents will improve glucose uptake.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net Tissue-type Plasminogen Activator (t-PA) Release</measure>
    <time_frame>During and after each study drug administration</time_frame>
    <description>Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forearm Blood Flow (FBF)</measure>
    <time_frame>During and after each study drug administration</time_frame>
    <description>Forearm blood flow was measured by strain gauge plethysmography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Net Glucose Uptake</measure>
    <time_frame>At baseline and after maximum dose of bradykinin</time_frame>
    <description>Individual net reuptake rates at each time point were calculated by the following formula: net uptake = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of glucose in the brachial vein and artery, respectively.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Control (bradykinin infusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bradykinin (Clinalfa AG, Läufelfingen, Switzerland)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-NMMA + bradykinin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-monomethyl-L-arginine (L-NMMA, NO synthase inhibitor; Bachem, Torrance, CA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isosorbide + L-NMMA + bradykinin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isosorbide (NO donor)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil + L-NMMA + bradykinin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil (phosphodiesterase type 5 (PDE5) inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control (bradykinin)</intervention_name>
    <description>Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.</description>
    <arm_group_label>Control (bradykinin infusion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-NMMA + bradykinin</intervention_name>
    <description>Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.</description>
    <arm_group_label>L-NMMA + bradykinin</arm_group_label>
    <other_name>N-monomethyl-L-arginine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide + L-NMMA + bradykinin</intervention_name>
    <description>Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.</description>
    <arm_group_label>Isosorbide + L-NMMA + bradykinin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil + L-NMMA + bradykinin</intervention_name>
    <description>Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.</description>
    <arm_group_label>Sildenafil + L-NMMA + bradykinin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 years of age

          -  Male and female subjects

          -  Surgical sterilization

          -  Childbearing potential: beta HCG on study day

          -  Subjects with a body mass index of 25 or greater

        Exclusion Criteria:

          -  Diabetes type 1 to type 2 as defined by a fasting glucose of 126 mg/dl or greater or
             the use of anti-diabetic medication

          -  Use of hormone replacement therapy

          -  Statin therapy

          -  In hypertensive subjects, a seated systolic blood pressure greater than 179 mmHg or a
             seated diastolic blood pressure greater than 110 mmHg or taking hypertensives

          -  Pregnancy/Breast Feeding

          -  Cardiovascular disease such as myocardial infarction with 6 months prior to
             enrollment, presence of angina pectoris, significant arrhythmia, congestive heart
             failure (LV hypertrophy acceptable) deep vein thrombosis, pulmonary embolism, second
             or three degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic
             cardiomyopathy

          -  Treatment with anticoagulants

          -  History of serious neurologic disease such as cerebral hemorrhage, stroke or transient
             ischemic attack

          -  Diagnosis of asthma

          -  Clinically significant gastrointestinal impairment that could interfere with drug
             absorption

          -  Hematocrit &lt;35%

          -  Hyperlipidemic fasting Total Cholesterol &gt;220mg/dl

          -  Impaired renal function (Serum creatinine &gt;1.5 mg/dl)

          -  History or presence of immunological or hematological disorders

          -  Any underlying or acute disease requiring regular medication which could possible pose
             a threat to the subject or make implementation of the protocol or interpretation of
             the study results difficult

          -  Impaired hepatic function (Serum glutamic oxaloacetic transaminase, serum glutamate
             pyruvate transaminase &gt; 60)

          -  Treatment with chronic systemic glucocorticoid therapy (more than 7 days in 1 month)

          -  Treatment with lithium salts

          -  History of Alcohol or drug abuse

          -  Treatment with any investigational drug 1 month preceding study

          -  Mental conditions rendering the subject unable to understand the nature, scope and
             possible consequences of the study

          -  Inability to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center-GCRC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pretorius M, Brown NJ. Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but attenuates vascular tissue-type plasminogen activator release. J Pharmacol Exp Ther. 2010 Jan;332(1):291-7. doi: 10.1124/jpet.109.160168. Epub 2009 Oct 19.</citation>
    <PMID>19841473</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <results_first_submitted>August 25, 2011</results_first_submitted>
  <results_first_submitted_qc>January 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2013</results_first_posted>
  <last_update_submitted>January 21, 2013</last_update_submitted>
  <last_update_submitted_qc>January 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown</investigator_full_name>
    <investigator_title>Professor of Medicine and Clinical Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Bradykinin</keyword>
  <keyword>Obesity</keyword>
  <keyword>Nitric Oxide Donor</keyword>
  <keyword>tissue type plasminogen activator</keyword>
  <keyword>isosorbide dinitrate</keyword>
  <keyword>phosphodiesterase inhibitor</keyword>
  <keyword>Renin-Angiotensin Aldosterone System</keyword>
  <keyword>Fibrinolysis</keyword>
  <keyword>Angiotensin converting enzyme</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Bradykinin</mesh_term>
    <mesh_term>omega-N-Methylarginine</mesh_term>
    <mesh_term>Kininogens</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from a volunteer registry at Vanderbilt University. Subjects who participated in prior studies and requested to be contacted for future studies were included in the recruitment process. Recruitment began on 12/07 and stopped on 1/09.</recruitment_details>
      <pre_assignment_details>Subjects with renal, endocrine, hematological or cardiovascular disease (including hypertension defined as an untreated systolic/diastolic blood pressure greater than 140/90 mmHg were excluded. Subjects with a fasting cholesterol greater than 5.7 mmol/L (220 mg/dl) and smokers were excluded. No washout period was required for the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>24 subjects received a bradykinin infusion and then a bradykinin + L-NMMA infusion. Subjects were then randomized to receive either isosorbide (N=12) or sildenafil (N=12). The infusion of bradykinin + L-NMMA was then repeated.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Control (Bradykinin Infusion)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24">A total of 24 subjects received an infusion of bradykinin</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>L-NMMA + Bradykinin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Isosorbide + L-NMMA + Bradykinin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Sildenafil + L-NMMA + Bradykinin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Subjects characteristics for all 24 participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.71" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Net Tissue-type Plasminogen Activator (t-PA) Release</title>
        <description>Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively.</description>
        <time_frame>During and after each study drug administration</time_frame>
        <population>Twenty four subjects were studied. One subject was excluded because of erroneous drug administration. Analysis was per protocol. Twenty-three subjects receive bradykinin then L-NMMA plus bradykinin infusions. Subjects were then randomized to either isosorbide or sildenafil. Twelve subjects received sildenafil and 11 subjects received isosorbide.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects received bradykinin at 50, 100 and 200ng/min</description>
          </group>
          <group group_id="O2">
            <title>L-NMMA + Control</title>
            <description>After the intial bradykinin infusion subjects then received a continuous infusion of L-NMMA plus bradykinin at 50, 100 and 200ng/min</description>
          </group>
          <group group_id="O3">
            <title>Isosorbide + L-NMMA + Control</title>
            <description>Eleven of the twenty-four subjects were randomized to isosorbide after completing the bradykinin and bradykinin plus L-NMMA infusions. The bradykinin plus L-NMMA infusions were then repeated.</description>
          </group>
          <group group_id="O4">
            <title>Sildenafil + L-NMMA + Control</title>
            <description>Twelve of the twenty-four subjects were randomized to sildenafil after completing the bradykinin and bradykinin plus L-NMMA infusions. After 1 hour, bradykinin plus L-NMMA infusions were repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Net Tissue-type Plasminogen Activator (t-PA) Release</title>
          <description>Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively.</description>
          <population>Twenty four subjects were studied. One subject was excluded because of erroneous drug administration. Analysis was per protocol. Twenty-three subjects receive bradykinin then L-NMMA plus bradykinin infusions. Subjects were then randomized to either isosorbide or sildenafil. Twelve subjects received sildenafil and 11 subjects received isosorbide.</population>
          <units>ng/min/100ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Net t-PA release (bradykinin 0ng/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.39"/>
                    <measurement group_id="O2" value="0.59" spread="0.23"/>
                    <measurement group_id="O3" value="-0.38" spread="0.51"/>
                    <measurement group_id="O4" value="0.29" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Net t-PA release (bradykinin 50ng/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="1.06"/>
                    <measurement group_id="O2" value="3.65" spread="0.79"/>
                    <measurement group_id="O3" value="3.14" spread="1.13"/>
                    <measurement group_id="O4" value="2.46" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Net t-PA release (bradykinin 100ng/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.81" spread="2.12"/>
                    <measurement group_id="O2" value="22.10" spread="5.51"/>
                    <measurement group_id="O3" value="15.90" spread="3.13"/>
                    <measurement group_id="O4" value="18.48" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Net t-PA release (bradykinin 200ng/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.03" spread="4.24"/>
                    <measurement group_id="O2" value="39.90" spread="6.98"/>
                    <measurement group_id="O3" value="45.32" spread="9.45"/>
                    <measurement group_id="O4" value="37.39" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of bradykinin on net t-PA release was determined using general linear model-repeated measures ANOVA in which the between-subject variable was gender, and the within-subjects variables were drug (control, +L-NMMA, +L-NMMA plus isosorbide, or +L-NMMA plus sildenafil) and dose of bradykinin.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forearm Blood Flow (FBF)</title>
        <description>Forearm blood flow was measured by strain gauge plethysmography</description>
        <time_frame>During and after each study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects received bradykinin at 50, 100 and 200ng/min</description>
          </group>
          <group group_id="O2">
            <title>L-NMMA + Control</title>
            <description>Subjects received a continuous infusion of L-NMMA plus bradykinin at 50, 100 and 200ng/min</description>
          </group>
          <group group_id="O3">
            <title>Isosorbide + L-NMMA + Control</title>
            <description>Twelve (of the twenty-four)subjects received isosorbide after completing the bradykinin and bradykinin plus L-NMMA infusions. The bradykinin plus L-NMMA infusions were then repeated.</description>
          </group>
          <group group_id="O4">
            <title>Sildenafil + L-NMMA + Control</title>
            <description>Twelve (of the twenty-four) subjects received sildenafil after completing the bradykinin and bradykinin plus L-NMMA infusions. After 1 hour, bradykinin plus L-NMMA infusions were repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Forearm Blood Flow (FBF)</title>
          <description>Forearm blood flow was measured by strain gauge plethysmography</description>
          <units>ml/min/100ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FBF (bradykinin 0 ng/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="0.25"/>
                    <measurement group_id="O2" value="2.36" spread="0.18"/>
                    <measurement group_id="O3" value="2.18" spread="0.33"/>
                    <measurement group_id="O4" value="2.80" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBF (bradykinin 50ng/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" spread="0.57"/>
                    <measurement group_id="O2" value="5.16" spread="0.37"/>
                    <measurement group_id="O3" value="4.73" spread="0.70"/>
                    <measurement group_id="O4" value="5.87" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBF (bradykinin 100ng/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.17" spread="1.04"/>
                    <measurement group_id="O2" value="8.67" spread="0.81"/>
                    <measurement group_id="O3" value="6.83" spread="1.13"/>
                    <measurement group_id="O4" value="9.13" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBF (bradykinin 200 ng/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.74" spread="1.43"/>
                    <measurement group_id="O2" value="11.21" spread="1.12"/>
                    <measurement group_id="O3" value="9.91" spread="1.72"/>
                    <measurement group_id="O4" value="12.92" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Net Glucose Uptake</title>
        <description>Individual net reuptake rates at each time point were calculated by the following formula: net uptake = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of glucose in the brachial vein and artery, respectively.</description>
        <time_frame>At baseline and after maximum dose of bradykinin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subjects received bradykinin at 50, 100 and 200ng/min</description>
          </group>
          <group group_id="O2">
            <title>L-NMMA + Control</title>
            <description>Subjects received a continuous infusion of L-NMMA plus bradykinin at 50, 100 and 200ng/min</description>
          </group>
          <group group_id="O3">
            <title>Isosorbide + L-NMMA + Control</title>
            <description>Twelve (of the twenty-four)subjects received isosorbide after completing the bradykinin and bradykinin plus L-NMMA infusions. The bradykinin plus L-NMMA infusions were then repeated.</description>
          </group>
          <group group_id="O4">
            <title>Sildenafil + L-NMMA + Control</title>
            <description>Twelve (of the twenty-four) subjects received sildenafil after completing the bradykinin and bradykinin plus L-NMMA infusions. After 1 hour, bradykinin plus L-NMMA infusions were repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Net Glucose Uptake</title>
          <description>Individual net reuptake rates at each time point were calculated by the following formula: net uptake = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of glucose in the brachial vein and artery, respectively.</description>
          <units>microgram/min/100ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Net glucose uptake (bradykinin 0 ng/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.95" spread="22.894"/>
                    <measurement group_id="O2" value="-74.36" spread="7.125"/>
                    <measurement group_id="O3" value="-71.4" spread="27.74"/>
                    <measurement group_id="O4" value="-67.3" spread="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Net glucose uptake (bradykinin 200 ng/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-319.85" spread="97.109"/>
                    <measurement group_id="O2" value="-142.86" spread="49.935"/>
                    <measurement group_id="O3" value="-163.233" spread="36.504"/>
                    <measurement group_id="O4" value="-125.32" spread="45.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Subjects characteristics for all 24 participants</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>fainted</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>unexpected drug response</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mias Pretorius</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-343-0665</phone>
      <email>mias.pretorius@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

